Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
NCT04649710 · Bristol-Myers Squibb · PHASE1 · withdrawn · last registry update 2022-04-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGF1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-13Results posted on the registry: Bristol-Myers Squibb, BMS-986036 (NCT03486912)
- 2022-09-09Results posted on the registry: Bristol-Myers Squibb, BMS-986036 (NCT03486899)
- 2022-08-09Results posted on the registry: Meridian Bioscience, Inc., ¹³C-Methacetin Breath Test + BMS-986036 (NCT03611101)
- 2022-06-23Also stopped (terminated): Cellxpert Biotechnology Corp., PI-88 (NCT01402908)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision